Best Technology news & reviews
Latest
AI
Amazon
Apps
Biotech & Health
Climate
Cloud Computing
Commerce
Crypto
Enterprise
EVs
Fintech
Fundraising
Gadgets
Gaming
Google
Government & Policy
Hardware
Instagram
Layoffs
Media & Entertainment
Meta
Microsoft
Privacy
Robotics
Security
Social
Space
Startups
TikTok
Transportation
Venture
Events
Startup Battlefield
StrictlyVC
Newsletters
Podcasts
Videos
Partner Content
TechCrunch Brand Studio
Crunchboard
Contact Us
Indian online pharmacy PharmEasy’s valuation now stands at about $456 million, according to disclosures from its investor Janus Henderson, a 92% drop from its peak valuation of $5.6 billion.
The British American global asset firm’s Global Research Fund values its holding of 12.9 million shares in PharmEasy at $766,043, according to its latest filing for the period ending September. The fund had originally spent $9.4 million to acquire these shares.
The persistent low valuation comes despite PharmEasy securing more than $200 million in fresh capital earlier this year and preparing to file an initial public offering next year, TechCrunch earlier reported.
This follows PharmEasy launching a rights issue in 2023 amid funding crunch and obligation to pay off a debt. A rights issue allow companies to raise capital by giving shareholders the opportunity to purchase shares at a discount. Depending on the terms, shareholders can also be wiped out of their previous ownership structures if they don’t participate in a rights issue.
PharmEasy raised $417 million through the rights issue that was oversubscribed, according to PharmEasy co-founder Dharmil Sheth. A regulatory filing in April 2024 showed the startup had secured about $216 million.
The startup, backed by Prosus, Temasek, TPG and B Capital, operates one of the largest online pharmacy in India. The current valuation places PharmEasy’s worth well below some $600 million it paid to acquire diagnostic lab chain Thyrocare in 2021. Pharmeasy has raised over $1 billion to date.
The startup’s financial challenges emerged after it deferred an $843 million IPO planned for November 2021. It then turned to debt financing, including a $300 million loan from Goldman Sachs that proved problematic as the company struggled with repayment and raising new equity in a deteriorating market.
Topics
$132K – $149K, here’s what seed-stage founders pay early employees, based on data
GV, the VC team backed by Google, has a broad remit, but it can’t do one thing
Home for the holidays? Share this top cybersecurity advice with friends and family
OpenAI ‘considered’ building a humanoid robot: Report
Google is using Anthropic’s Claude to improve its Gemini AI
Watch Boston Dynamics’ electric Atlas do a backflip
Eero’s Outdoor 7 long-distance mesh unit solved our yearslong Wi-Fi quandary in 10 minutes
Subscribe for the industry’s biggest tech news
Every weekday and Sunday, you can get the best of TechCrunch’s coverage.
TechCrunch's AI experts cover the latest news in the fast-moving field.
Every Monday, gets you up to speed on the latest advances in aerospace.
Startups are the core of TechCrunch, so get our best coverage delivered weekly.
By submitting your email, you agree to our Terms and Privacy Notice.
© 2024 Yahoo.
